Treatment Clinical Trials for Carcinoma of Unknown Primary Origin

Clinical trials are research studies that involve people. The clinical trials on this list are for carcinoma of unknown primary origin treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-16 of 16
  • Radiation Therapy with Durvalumab or Cetuximab in Treating Patients with Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

    This phase II / III trial studies how well radiation therapy works with durvalumab or cetuximab in treating patients with head and neck cancer that has spread to a local and / or regional area of the body who cannot take cisplatin. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as durvalumab or cetuximab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not known if radiation therapy with durvalumab will work better than the usual therapy of radiation therapy with cetuximab in treating patients with head and neck cancer.
    Location: 221 locations

  • Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

    An international, multicenter, open-label, 2 cohort, non-comparative, pivotal study evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-HN). The first cohort will assess the objective response rate (ORR) of tipifarnib in subjects with HNSCC with HRAS mutations. The second study cohort, SEQ-HN, is an observational sub-study and includes 2 types of patients: (1) the historical record of first line therapy in subjects with HRAS mutant HNSCC participating in Cohort 1 in whom first line outcome data are available and (2) matched control HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who consent to provide first line outcome data and additional follow up.
    Location: 22 locations

  • Talimogene Laherparepvec and Nivolumab in Treating Patients with Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

    This phase II trial studies how well talimogene laherparepvec and nivolumab work in treating patients with lymphomas that do not responded to treatment (refractory) or non-melanoma skin cancers that have spread to other places in the body (advanced) or do not responded to treatment. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving talimogene laherparepvec and nivolumab may work better compared to usual treatments in treating patients with lymphomas or non-melanoma skin cancers.
    Location: 18 locations

  • Pembrolizumab and Cabozantinib in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer That Cannot Be Removed by Surgery

    This phase II trial studies how well pembrolizumab and cabozantinib work in treating patients with head and neck squamous cell cancer that has come back (recurrent) or spread to other places in the body (metastatic) and cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozntinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and cabozantinib may work better in treating patients with head and neck squamous cell cancer.
    Location: 3 locations

  • Cetuximab and Nivolumab in Treating Patients with Recurrent or Metastatic Oral Cavity, Oropharyngeal, Paranasal Sinus, Hypopharyngeal, or Laryngeal Cancer

    This phase I / II trial studies the side effects and how well cetuximab and nivolumab work in treating patients with oral cavity, oropharyngeal, paranasal sinus, hypopharyngeal, or laryngeal cancer that have come back (recurrent) or spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Some tumors need growth factors, which are made by the body's white blood cells, to keep growing. Growth factor inhibitors, such as cetuximab may interfere with the growth factor and stop the tumor from growing.
    Location: 3 locations

  • Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary

    Single-arm phase 2 study to examine pembrolizumab and concurrent radiation to induce an abscopal effect in patients with previously treated carcinoma of unknown primary (CUP16-268)
    Location: 2 locations

  • Combination Chemotherapy and Radiation Therapy in Treating Patients with Locally Advanced HPV Positive Oropharynx Cancer

    This phase II trial studies how well combination chemotherapy followed by reduced dose chemoradiation therapy works in curing patients with locally advanced human papillomavirus (HPV) positive oropharynx cancer. Drugs used in chemotherapy, such as docetaxel, cisplatin, fluorouracil and carboplatin work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving combination chemotherapy prior to chemoradiation therapy may result in be less early and late toxicity and side effects then standard chemoradiotherapy in HPV positive oropharynx cancer as there will be fewer side effects.
    Location: 2 locations

  • Nivolumab with Relatlimab or Ipilimumab for the Treatment of Recurrent and / or Metastatic Head and Neck Squamous Cell Cancer

    This phase II trial investigates how well nivolumab with relatlimab or ipilimumab work in treating patients with head and neck squamous cell cancer that has come back (recurrent) and / or has spread to other places in the body (metastatic) and has progressed on prior immunotherapy. Immunotherapy drugs are drugs that work by trying to get the immune system to attack cancer. Comparing the immune system to a car, there are two ways to make a car go faster. One is to press on the gas pedal and the other is to take the foot of the brake. The immune system has many “gas pedals” and “brakes” in order to help it decide whether to attack or not attack. The drugs nivolumab, relatlimab, and ipilimumab are antibodies (a type of protein) that work by blocking a “brake” (akin to taking the foot off the brake in the car) on the immune system cells which can lead to the immune system attacking the cancer. Each drug blocks a different brake. Nivolumab blocks PD-1, relatlimab blocks LAG-3, and ipilimumab blocks CTLA4. Giving nivolumab together with relatlimab or ipilimumab may cause the tumor to shrink in size.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Safety and Efficacy of Repeat Administration of Ad / PNP and Fludarabine Phosphate in Patients With Local Head / Neck Cancer

    Primary Objective: The primary objective of the study is to evaluate the safety of repeat administration of a dose level of Ad / PNP plus fludarabine phosphate (F-araAMP) which demonstrated anti-tumor activity in patients with advanced, locoregional head / neck cancer in a completed phase I study. Secondary Objective: The secondary objective is to evaluate the antitumor activity of repeat administration of Ad / PNP plus F-araAMP.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • Pembrolizumab, Cisplatin, and Intensity Modulated Radiation Therapy in Treating Patients with Previously Untreated Stage III-IVb Head and Neck Cancer

    This randomized phase II trial studies how well pembrolizumab works when given during or after cisplatin and intensity modulated radiation therapy in treating patients with previously untreated stage III-IVb head and neck cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. It is not yet known whether giving pembrolizumab during or after cisplatin and intensity modulated radiation therapy will kill more tumor cells.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • Mitomycin in Treating Patients with P16 Positive Oropharyngeal or P16 Negative Head and Neck Cancer That is Resistant to Platin, Fluorouracil, Cetuximab, and Taxane

    This phase II trial studies how well mitomycin works in treating patients with tumor protein (p)16 positive oropharyngeal or p16 negative head and neck squamous cell cancer that is resistant to platin, fluorouracil, cetuximab, and taxane. Drugs used in chemotherapy, such as mitomycin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • A Vaccine (ISA101b) and Pembrolizumab with Cisplatin and IMRT for the Treatment of Intermediate Risk HPV-16 Associated Head and Neck Squamous Cell Carcinoma

    This phase II trial investigates how well a vaccine (ISA101b) and pembrolizumab with cisplatin and IMRT work in treating patients with intermediate risk HPV-16 associated head and neck squamous cell carcinoma. ISA101b is a therapeutic vaccine aimed against infection with HPV-16. ISA101b consists of 12 proteins that stimulate the patient’s own immune system against the HPV-16 virus. By targeting these HPV proteins, the intention is to induce the immune response to control the HPV-16 infection and eliminate HPV-16-induced lesions (areas of abnormal tissue). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. IMRT is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. The goal of this trial is to determine if adding pembrolizumab and ISA101b to the approved treatment (cisplatin + radiation therapy) for head and neck cancer will lead to better survival rates and less instances of cancer returning.
    Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania

  • sEphB4-HSA in Combination with Chemotherapy or Cetuximab and Radiation Therapy for the Treatment of High Risk, Stage III-IVB Head and Neck Squamous Cell Carcinoma

    This phase I / Ib trial studies the side effects and best dose of sEphB4-HSA when given together with chemotherapy or cetuximab and radiation therapy in treating patients with high risk, stage III-IVB head and neck squamous cell carcinoma. sEphB4-HSA works by blocking one way tumors get a blood supply. Chemotherapy drugs, such as cisplatin or carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as cetuximab, may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving sEphB4-HSA with chemotherapy or cetuximab and radiation therapy may work better in treating patients with head and neck squamous cell carcinoma compared to cetuximab and radiation therapy alone.
    Location: University of Colorado, Denver, Colorado

  • Validation of Smartphone App for Head and Neck Cancer Control and Patient Support

    Vibrent Health is partnering with Stanford Cancer Center to conduct a randomized control trial (RCT) using mobile health technology to enhance adherence and improve swallowing outcomes in patients undergoing radiation therapy for head and neck cancer.
    Location: Stanford Cancer Institute Palo Alto, Palo Alto, California

  • Durvalumab with or without Metformin in Treating Patients with Head and Neck Squamous Cell Carcinoma

    This pilot phase I trial studies how well durvalumab given with or without metformin works in treating patients with head and neck squamous cell carcinoma. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Metformin, a drug typically used for the treatment of diabetes, may help to reduce the metabolic activity of cancer cells and of surrounding supportive tissues. It is not yet known whether giving durvalumab with or without metformin may work better in treating patients with head and neck squamous carcinoma.
    Location: Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

  • Pembrolizumab in Treating Patients with Rare Tumors That Cannot Be Removed by Surgery or are Metastatic

    This phase II trial studies how well pembrolizumab works in treating patients with rare tumors that cannot be removed by surgery or have spread to other parts of the body (metastatic). Monoclonal antibodies, such as pembrolizumab, may block specific proteins found on white blood cells which may strengthen the immune system and control tumor growth.
    Location: M D Anderson Cancer Center, Houston, Texas